Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Cost of RevenueDepreciation & Amortization (IS)EBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Insight Molecular Diagnostics (IMDX) Cost of Revenue (2016 - 2026)

Insight Molecular Diagnostics' Cost of Revenue history spans 6 years, with the latest figure at -$2.3 million for Q4 2025.

  • On a quarterly basis, Cost of Revenue fell 291.51% to -$2.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $458000.0, a 85.33% decrease, with the full-year FY2025 number at $1.8 million, down 55.63% from a year prior.
  • Cost of Revenue hit -$2.3 million in Q4 2025 for Insight Molecular Diagnostics, down from $1.4 million in the prior quarter.
  • Over the last five years, Cost of Revenue for IMDX hit a ceiling of $3.3 million in Q4 2021 and a floor of -$2.3 million in Q4 2025.
  • Historically, Cost of Revenue has averaged $740600.0 across 5 years, with a median of $716500.0 in 2021.
  • Biggest five-year swings in Cost of Revenue: tumbled 535.61% in 2023 and later soared 555.97% in 2024.
  • Tracing IMDX's Cost of Revenue over 5 years: stood at $3.3 million in 2021, then tumbled by 91.6% to $278000.0 in 2022, then tumbled by 535.61% to -$1.2 million in 2023, then surged by 199.26% to $1.2 million in 2024, then crashed by 291.51% to -$2.3 million in 2025.
  • Business Quant data shows Cost of Revenue for IMDX at -$2.3 million in Q4 2025, $1.4 million in Q3 2025, and $168000.0 in Q2 2025.